

**CLINICAL PROTOCOL  
NAPROXEN SODIUM**

**CCSPAA000457**

**A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-  
CONTROLLED, EFFICACY AND SAFETY STUDY OF A TEST  
NAPROXEN SODIUM 220 MG TABLET IN POSTOPERATIVE  
DENTAL PAIN**

<b>Investigational Product Name:</b>	Naproxen Sodium
<b>Protocol Number:</b>	CCSPAA000457
<b>IND / IDE / EudraCT number:</b>	135,012
<b>Phase:</b>	3
<b>Version (Final) Date:</b>	Version 1 (Final): 11 May 2018
	Version 2: Administrative Change/Non-substantial Amendment 1 - 19 July 2018

This document contains privileged and confidential information belonging to the Sponsor. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold the information contained herein in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event information is disclosed to others, as required by applicable law, they must be informed that the information is privileged and confidential and may not be further disclosed by them. These restrictions on disclosures will apply equally to all future information supplied to you that is indicated as privileged and confidential. You agree that no unpublished information contained herein will be published or disclosed without the prior written approval of Sponsor. In the event of any actual or suspected breach of this obligation, Sponsor must be promptly notified.

**COMPANY CONFIDENTIAL**

## 1. SYNOPSIS

<b>Name and address of the Sponsor/Company of the clinical investigation:</b> Johnson & Johnson Consumer, Inc., McNeil Consumer Healthcare Division [REDACTED] [REDACTED]
<b>Active Ingredient(s):</b> Test Naproxen Sodium, 220 mg Tablet (440 mg dose as two 220 mg tablets) (Test NPX)
<b>Title of Study:</b> A Randomized, Double-Blind, Placebo- and Active- Controlled, Efficacy and Safety Study of a Test Naproxen Sodium 220 mg Tablet in Postoperative Dental Pain
<b>Country:</b> USA
<b>Phase of development:</b> 3
<b>Objective:</b> To evaluate analgesic onset, efficacy, and safety of a single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX) compared with two commercial naproxen sodium products (two [REDACTED] 220 mg tablets and two [REDACTED] 220 mg [REDACTED] capsules) and placebo in the dental pain model following third-molar extractions.
<b>Methodology:</b> This will be a single-dose, randomized, double-blind, placebo- and active- controlled, parallel-group study to evaluate the analgesic onset, efficacy, and safety profile of 440 mg of naproxen sodium administered as two Test NPX 220 mg tablets compared with two commercial products and placebo over a twelve-hour period after third-molar extractions. Subjects will undergo dental extraction of three or four third molars. Maxillary third molars may be removed regardless of impaction level. The mandibular extractions must meet one of the following scenarios and must not result in a trauma rating of severe on a mild, moderate, or severe scale: <ul style="list-style-type: none"><li>• two full bony impactions</li><li>• two partial bony impactions</li><li>• one full bony impaction in combination with one partial bony impaction</li></ul> Pain assessments will be based on subject self-report. Subjects who meet the randomization criteria (post-surgical pain of moderate to severe on the four-point categorical pain scale [0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain], and at least a score of 5 on the 11-point [0-10] pain intensity numerical rating scale [PI-NRS] at baseline within 4.5 hours of last stitch from dental extractions) will be assigned to one of four treatment groups. This PI-NRS will be within 5 minutes prior to study medication dosing and will be considered the time 0 pain intensity assessment.  Approximately 500 subjects will receive a single 440 mg dose of either Test NPX, [REDACTED]

COMPANY CONFIDENTIAL

tablets, [REDACTED] capsules, or placebo in a 3:3:3:1 allocation ratio, and will be stratified according to gender and baseline pain rating (moderate or severe). To maintain the double-blind nature of the study, an independent third party will administer study drug to blindfolded subjects. No less than approximately 30% of randomized subjects will be either male or female. In addition, no more than approximately 30% of subjects will be 17 years of age at the time of screening.

[REDACTED]  
[REDACTED]. Perceptible pain relief and meaningful pain relief will be collected using two separate stopwatches. Subjects who do not experience pain relief after dosing will be encouraged but not required to wait at least 1.5 hours before using rescue medication. [REDACTED]  
[REDACTED].

After completion of all study assessments, subjects will be discharged from the study site. Subjects will be interviewed by telephone to follow up on appropriate postsurgical medical care and changes in their health, including any emergent or existing adverse events (AEs). The interview will occur between Day 6 through 10.

**Number of subjects (planned):**

Approximately 500

**Diagnosis and main criteria for inclusion in the study:**

Subjects 17 to 50 years of age who meet the inclusion and exclusion criteria, which includes surgical extraction of three or four third molars resulting in at least moderate pain on the categorical scale and a pain intensity of  $\geq 5$  on a 0 to 10 scale, will be eligible for the study.

**Study product, dosage and mode of administration:**

Depending on randomization, to maintain the double-blind nature of the study, an independent third party will administer a single 440-mg dose of naproxen sodium as two Test NPX 220 mg tablets to blindfolded subjects. Subjects will swallow the dose with up to 180 mL water at ambient temperature.

**Reference therapy (comparator or placebo control), dosage and mode of administration:**

Depending on randomization, an independent third party will administer one of the following reference products with up to 180 ml water at ambient temperature to blindfolded subjects:

- a single 440-mg dose of naproxen sodium as two [REDACTED] 220 mg tablets;
- a single 440-mg dose of naproxen sodium as two [REDACTED] 220 mg [REDACTED] capsules; or
- a single dose of two placebo tablets.

**Duration of treatment:**

One dose: subjects will remain at the study site for 12 hours after dosing whether or not the subject rescues, vomits, or experiences other AEs.

**Endpoints:**

COMPANY CONFIDENTIAL

**Primary Efficacy Endpoint**

- Time to confirmed perceptible pain relief (TCPR)

**Secondary Efficacy Endpoint**

- Percentage of subjects with confirmed perceptible pain relief from 45 minutes to successively earlier minutes in one-minute increments (Test NPX versus PBO)

[REDACTED]

**Safety:**

Safety will be monitored and assessed by reviewing the collection, evaluation, and analysis of AEs. Any causally related AE that is unresolved upon completion of the last study visit will be followed by the Investigator until the event, or its sequelae, resolves or stabilizes at a level acceptable to the Investigator.

**Statistical methods:**

[REDACTED]. The survival function (cumulative proportions of subjects with pain relief at each time point) and the median survival time will be estimated by the Kaplan-Meier method for each treatment. The survival functions will be compared using the Wilcoxon test.

The earliest time of separation of confirmed perceptible pain relief between Test NPX and placebo will be established by comparing the percentage of subjects with confirmed perceptible pain relief starting from 45 minutes to successively earlier minutes in one-minute increments, until statistical significance is no longer achieved. The dichotomized response will be analyzed using logistic regression analysis. [REDACTED]

To control the family-wise Type I error rate at 0.05 for the primary endpoint (TCPR) and the secondary endpoint of percentage of subjects with confirmed perceptible pain relief from 45 minutes to successively earlier minutes, a fixed sequence testing with fallback method will be used. [Table 1](#) presents the order of the tests and the assigned  $\alpha$  values for each ordered test. Testing will commence with an assigned alpha = 0.049 and an alpha value of 0.001 will be reserved for the comparison of Test NPX and placebo on the percentage of subjects with confirmed perceptible relief from 45 minutes to successively earlier minutes in one-minute

increments.

**Table 1 Order of Tests and Assigned Alpha Values**

	Pre-Assigned $\alpha$	$\alpha$ available if previous test positive	$\alpha$ available if previous test negative
TCPR: Test NPX vs Placebo	0.049	Not Applicable	Not Applicable
TCPR: Test NPX vs [REDACTED]	None	0.049	None
TCPR: Test NPX vs [REDACTED]	None	0.049	None
Percentage subjects with confirmed perceptible pain relief from 45 to successively earlier minutes: Test NPX vs Placebo	0.001	0.05	0.001

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

## 2. STUDY FLOW CHART AND SCHEDULE OF ACTIVITIES

**Table 2: Schedule of Activities**

	Screening	Baseline (Day of Surgery)	Hours Post-Dose	Follow-Up Call/End of Study
Procedures	Day -30 to 1	Day 1	0 to 12 hours	Day 6 - 10
Written informed consent and/or assent	X			
Demography (including age)	X			
Inclusion / Exclusion Assessment	X	X		
Significant medical history	X	X		
Vital signs	X	X		
Physical Exam (Height, weight and BMI)	X			
Urine pregnancy test (Females of childbearing potential)	X	X		
Urine drug screen	X	X		
Serology	X			
Dental extraction surgery		X		
Baseline Pain Assessments (Categorical and PI-NRS)		X <sup>1</sup>		
Randomization criteria		X		
Investigational product administration		X		
Stopwatch Assessments (perceptible & meaningful pain relief)			X	
			X	
Rescue therapy			X <sup>3</sup>	
			X <sup>4</sup>	
Prior and Concomitant Therapy	X	X	X	X <sup>5</sup>
Safety monitoring <sup>6</sup>	X	X	X	X
Subject Disposition				X <sup>7</sup>

<sup>1</sup>Scored within 4.5 hours after last stitch from dental surgery; <sup>2</sup>

medicine; <sup>3</sup>Subjects encouraged to wait at least 1.5 hours after investigational product administration before using rescue

medicine; <sup>4</sup>Subjects encouraged to wait at least 1.5 hours after investigational product administration before using rescue medicine; <sup>5</sup> Medications and other treatments taken after 12-hour assessment period through follow-up interview will be captured on source documents and only those taken for or associated with an AE will be recorded in the CRF; <sup>6</sup>Collection of AEs and report of pregnancy; <sup>7</sup> End of Study for each subject is defined as the follow-up phone call or early termination.

COMPANY CONFIDENTIAL

**TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES**

1.	SYNOPSIS .....	2
2.	STUDY FLOW CHART AND SCHEDULE OF ACTIVITIES .....	6
3.	LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.....	12
4.	ETHICS .....	13
4.1.	Institutional Review Board (IRB) / Independent Ethics Committee (IEC).....	13
4.2.	Ethical and Regulatory Considerations .....	13
4.3.	Subject Information and Consent .....	13
4.4.	Subject Written Assent .....	14
5.	STUDY ADMINISTRATIVE STRUCTURE .....	15
6.	INTRODUCTION .....	16
7.	STUDY OBJECTIVES AND ENDPOINTS.....	17
7.1.	STUDY ENDPOINTS.....	17
7.1.1.	Primary Efficacy Endpoint .....	17
7.1.2.	Secondary Efficacy Endpoint .....	17
7.1.3.	.....	17
7.2.	Safety .....	17
8.	INVESTIGATIONAL PLAN.....	18
8.1.	Overall Study Design and Plan.....	18
8.2.	End of Study for Each Subject.....	19
8.3.	Sponsor Discontinuation Criteria .....	19
9.	STUDY POPULATION .....	21
9.1.	Subject Eligibility Criteria.....	21
9.1.1.	Subject Inclusion Criteria .....	21
9.1.2.	Exclusion Criteria .....	22
9.2.	Subject Withdrawal/Termination Criteria .....	23
9.3.	Life Style Guidelines .....	24
9.3.1.	Meals and Dietary Restrictions.....	24
9.3.2.	Alcohol, Caffeine and Tobacco Consumption / Restrictions .....	24

9.3.3.	Physical Activity Requirements / Restrictions .....	24
9.3.4.	Contraception for Females.....	24
9.3.5.	Contraception for Males .....	25
10.	STUDY INTERVENTION .....	27
10.1.	Description and Administration.....	27
10.2.	Packaging and Labeling.....	27
10.3.	Preparation, Handling and Disposal .....	27
10.4.	Storage and Accountability.....	29
10.5.	Randomization/Treatment Allocation .....	30
10.6.	Blinding and Unblinding .....	30
10.7.	Treatment Compliance.....	30
10.8.	Previous and Concomitant Medications .....	31
10.8.1.	Permitted Therapies .....	31
10.8.2.	Prohibited Therapies .....	31
10.9.	Rescue Therapy .....	31
10.10.	Product Quality Complaints .....	31
11.	STUDY PROCEDURES .....	33
11.1.	Overview.....	33
11.2.	Screening Visit.....	33
11.3.	Baseline Visit (Day of Surgery) .....	33
11.4.	Randomization.....	34
11.5.	Post dose Assessments.....	34
11.6.	Follow-Up Phone call .....	35
12.	ASSESSMENTS.....	36
12.1.	Efficacy Assessments .....	36
12.2.	Safety Assessments.....	36
12.2.1.	Physical Examination .....	37
12.2.2.	Vital Signs .....	37
12.2.3.	Clinical Laboratory Tests .....	37



13.	ADVERSE EVENTS.....	38
13.1.	Definitions .....	38
13.1.1.	Definition of Adverse Event.....	38
13.1.2.	Definition of Serious Adverse Events (SAE) for Drugs.....	39
13.2.	Adverse Event Assessments .....	41
13.2.1.	Severity Assessment .....	41
13.2.2.	Causality Assessment .....	42
13.2.3.	Resolution .....	43
13.3.	Adverse Event Reporting.....	43
13.3.1.	Time Period .....	43
13.3.2.	Process for Reporting .....	43
13.4.	Suspected Unexpected Serious Adverse Reaction .....	45
13.5.	Special Situations.....	45
13.5.1.	Exposure In Utero.....	45
14.	STATISTICS .....	47
14.1.	Sample Size Determination .....	47
14.1.1.	Efficacy Analyses Sets .....	47
14.1.2.	Safety Analysis Population.....	47
14.2.	Baseline and Demographics .....	47
14.3.	Previous and Concomitant Medications .....	48
14.4.	Efficacy Analysis.....	48
14.5.	Statistical Hypotheses and Treatment Comparisons.....	48
14.6.	Data Computations and Data Imputations.....	49
14.6.1.	Time to [REDACTED] Confirmed Perceptible, [REDACTED] Pain Relief ( [REDACTED] TCPR [REDACTED] ).....	49
14.6.2.	[REDACTED].....	50
14.7.	Analysis Methods .....	50
14.7.1.	[REDACTED].....	50

14.7.2.	Earliest Statistically Significant Separation of Test NPX and Placebo on Percentage of Subjects with Confirmed Perceptible Relief.....	51
14.7.3.	[REDACTED].....	51
14.7.4.	[REDACTED].....	51
14.7.5.	[REDACTED].....	51
14.7.6.	[REDACTED].....	51
14.7.7.	[REDACTED].....	51
14.7.8.	Subgroup Analyses .....	51
14.8.	Safety Analysis .....	52
14.8.1.	Adverse Events .....	52
15.	DIRECT ACCESS TO SOURCE DATA/DOCUMENTS.....	53
15.1.	Study Monitoring.....	53
15.2.	Audits and Inspections.....	54
16.	QUALITY CONTROL AND QUALITY ASSURANCE .....	55
17.	DATA HANDLING AND RECORDKEEPING .....	56
17.1.	Case Report Forms / Electronic Data Capture.....	56
17.2.	Source Documents.....	56
17.3.	Inspection and Retention of Records.....	56
18.	PUBLICATION POLICY .....	57
19.	LIST OF REFERENCES.....	58
20.	APPENDICES .....	59

**LIST OF TABLES**

Table 1	Order of Tests and Assigned Alpha Values.....	5
Table 2:	Schedule of Activities.....	6
Table 3:	Abbreviations and Specialist Terms .....	12
Table 4:	Investigational Product .....	27
Table 5:	Order of Tests and Assigned Alpha Values.....	49

Test Naproxen Sodium 220 mg Tablet  
Protocol: CCSPAA000457  
Version 1: 11 May 2018  
Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

**LIST OF FIGURES**

Figure 1: Study Design.....19

### 3. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

The following abbreviations and specialist terms are used in this study protocol.

**Table 3: Abbreviations and Specialist Terms**

Abbreviation/ Term	Definition
AE	Adverse event
BMI	Body Mass Index
CRF	Case report form
EDC	Electronic data capture
EIU	Exposure in Utero
ICH GCP	International Conference on Harmonization Good Clinical Practice
IRB/IEC	Institutional Review Board/Independent Ethics Committee
IP	Investigational Product
JJCI	Johnson and Johnson Consumer, Inc.
NPX	Naproxen Sodium
NSAID	Nonsteroidal anti-inflammatory drug
OTC	Over-the-counter
████	████
PI	Principal Investigator
████	████
PQC	Product Quality Complaint
PI-NRS	Pain intensity-numerical rating scale
████	████
SAE	Serious adverse event
████	████
████	████
TCPR	Time to confirmed perceptible pain relief
████	████
████	████

## **4. ETHICS**

### **4.1. Institutional Review Board (IRB) / Independent Ethics Committee (IEC)**

It is the responsibility of the Sponsor and Investigator to have prospective approval of the study protocol, protocol amendments, informed consent forms, and other relevant documents, e.g., advertisements, if applicable, from the IRB/IEC. All correspondence with the IRB/IEC should be retained in the Investigator File (Site Master File). Copies of IRB/IEC approvals obtained by the Investigator should be forwarded to the Sponsor.

The only circumstance in which a protocol amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the subjects. In that event, the Investigator must notify the IRB/IEC and the Sponsor in writing within 5 working days after implementation.

### **4.2. Ethical and Regulatory Considerations**

The study will be performed in accordance with the protocol, International Council for Harmonization, Good Clinical Practice (ICH GCP) guidelines (ICH E6) and applicable local regulatory requirements and laws.

Before initiating the clinical study, the Sponsor should submit any required application(s) to the appropriate authority (ies) for review, acceptance, and/or permission to begin the study. Any notification/submission should be dated and contain sufficient information to identify the protocol.

Amendments to the protocol that are considered as substantial, i.e., are likely to have an impact on the safety of the study subjects, to change the interpretation of the scientific documents in support of the conduct of the study, or if they are otherwise significant, must be reviewed and approved by the appropriate authority(ies).

### **4.3. Subject Information and Consent**

All parties will ensure protection of subject personal data and will not include subject names or subject initials on any forms, reports, publications, or in any other disclosures. Each subject will be assigned a subject number that is used in the Case Report Form (CRF) in lieu of the subject's name. In case of data transfer, the Sponsor will maintain high standards of confidentiality and protection of subject personal data.

The informed consent form must be agreed to by the Sponsor and the IRB/IEC. It must be in compliance with current regulatory requirements (e.g., ICH E6), and legal requirements, and

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

be in a language that the subject can read and understand with compliance to the International Standard and any regional or national regulations, as appropriate.

The Investigator must ensure that each study subject is fully informed about the nature and objectives of the study and possible risks associated with participation in the study. The Investigator, or a person designated by the Investigator, will obtain written informed consent from each subject, or legally authorized representative, before any study-specific activity is performed. The informed consent form used in this study, and any changes made during the course of the study, must be prospectively approved by both the IRB/IEC and the Sponsor before use. The Investigator will retain the original of each subject's signed consent form. A copy of the signed and dated consent form will be provided to subjects.

Only subjects who provide informed consent will be permitted to participate in the study.

#### **4.4. Subject Written Assent**

After the informed consent form is signed and dated by the parents or legally authorized representatives and witnessed by a member of the investigator's clinical team, written assent to participate in the study must be obtained from prospective subjects who are below the age of legal consent yet old enough to understand details of the study as required by the site's IRB/IEC or Principal Investigator (PI), or local requirements. During the assent process, the PI or designee will provide the minor with an assent document that explains, in terms appropriate to the child's age, experience, maturity and condition, any discomfort and inconveniences the child may expect to experience if he or she agrees to participate. The subject should also be made aware of his or her rights to decline participation or to withdraw from the study at any time. The assent document will focus on the risks, benefits and alternatives to research participation as well as confidentiality of information obtained as a result of their participation. The minor should be given an opportunity to ask questions prior to signing the approved assent form or designated assent signature line within the Informed Consent Form. A witness must also sign and date the assent form. The original signed assent form will be retained by the investigator as part of the source documents/study files and will be available for review by the monitor and the Sponsor. A copy of the signed and dated assent form will be given to the subject. Assent by the subject acknowledges willingness to participate, but does not necessarily ensure a thorough understanding of the procedures, risks and benefits of the study.

**COMPANY CONFIDENTIAL**

## **5. STUDY ADMINISTRATIVE STRUCTURE**

Details on the administrative structure of the study (e.g., PI/study site personnel, the Sponsor's study team, and the external service providers) will be included in the study contact list. The study contact list will also include contact information for the Sponsor, Investigator(s), Monitor(s), Clinical and Bioanalytical Laboratories, and IRB/IEC(s), as well as the names and titles of the person(s) authorized to sign the protocol and the protocol amendment(s) for the Sponsor. The complete contact list will be maintained in the trial master file throughout the study for inclusion in the clinical study report.

## 6. INTRODUCTION

Naproxen is a propionic acid derivative and nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. The mechanism of action of naproxen involves inhibition of cyclooxygenase enzymes resulting in decreased prostaglandin synthesis. The sodium salt of naproxen has been developed as a more rapidly absorbed formulation of naproxen. Naproxen sodium products have been available over-the-counter (OTC) for the indications of fever reduction and relief of minor aches and pains in several countries for many years.

In the United States, naproxen sodium has been available as an OTC analgesic and antipyretic since 1994. It is indicated for OTC use for the temporary relief of minor aches and pains due to: minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, toothache, and the common cold, and for temporary reduction of fever. According to the Drug Facts for [REDACTED], dosing for adults and children 12 years of age and older is one 220 mg dosage unit (e.g., tablet, caplet, capsule) every 8-12 hours, and for the first dose, may take two 220 mg units within the first hour. [REDACTED]

Clinical efficacy and safety studies have not yet been conducted on the [REDACTED] formulation of naproxen sodium. The current study will evaluate the analgesic onset, efficacy and safety of a single 440 mg dose of [REDACTED] naproxen sodium (administered as two 220 mg tablets) compared to two currently marketed [REDACTED] formulations of naproxen sodium and placebo after third molar dental extractions. The postoperative dental pain model is a validated model of acute pain that is widely used to study analgesic efficacy of compounds [1] [2].



## 7. STUDY OBJECTIVES AND ENDPOINTS

### Primary Objective:

To evaluate analgesic onset, efficacy, and safety of a single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX) compared with two commercial naproxen sodium products (two [REDACTED] 220 mg tablets and two [REDACTED] 220 mg [REDACTED] capsules) and placebo in the dental pain model following third-molar extractions.

### 7.1. STUDY ENDPOINTS

#### 7.1.1. Primary Efficacy Endpoint

- Time to confirmed perceptible pain relief (TCPR)

#### 7.1.2. Secondary Efficacy Endpoint

- Percentage of subjects with confirmed perceptible pain relief from 45 minutes to successively earlier minutes in one-minute increments (Test NPX versus PBO)

#### 7.1.3. Tertiary Efficacy Endpoints

- [REDACTED]

### 7.2. Safety

Safety will be monitored and assessed by reviewing the collection, evaluation, and analysis of AEs.

## 8. INVESTIGATIONAL PLAN

### 8.1. Overall Study Design and Plan

This is a single-dose, randomized, double-blind, placebo- and active- controlled, parallel-group study to evaluate the analgesic onset, efficacy, and safety profile of 440 mg of naproxen sodium administered as two Test NPX 220 mg tablets compared with two commercial products and placebo over a 12-hour period after third-molar extractions (Figure 1). Subjects will undergo dental extraction of three or four third molars. Maxillary third molars may be removed regardless of impaction level. The mandibular extractions must meet one of the following scenarios and must not result in a trauma rating of severe in a mild, moderate, or severe scale:

- two full bony impactions
- two partial bony impactions
- one full bony impaction in combination with one partial bony impaction

Pain assessments will be based on subject self-report. Subjects who meet the randomization criteria (post-surgical pain of moderate to severe on the four-point categorical pain scale [0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain], and at least a score of 5 on the 11-point [0-10] pain intensity numerical rating scale [PI-NRS] at baseline within 4.5 hours of last stitch from dental extractions) will be assigned to one of four treatment groups. This PI-NRS will be within 5 minutes prior to study medication dosing and will be considered the time 0 pain intensity assessment.

Approximately 500 subjects will receive a single 440 mg dose of either Test NPX, [REDACTED] tablets, [REDACTED] capsules, or placebo in a 3:3:3:1 allocation ratio, and will be stratified according to gender and baseline pain rating (moderate or severe). To maintain the double-blind nature of the study, an independent third party will administer study drug to blindfolded subjects. No less than approximately 30% of randomized subjects will be either male or female. In addition, no more than approximately 30% of subjects will be 17 years of age at the time of screening.

Pain intensity (PI-NRS) [REDACTED] (using the 11-point [0-10] pain relief numerical rating scale [PR-NRS]) will be collected at ee post dose as well as at the time of rescue (if applicable) before administration [REDACTED]. Perceptible pain relief and meaningful pain relief will be collected using two separate stopwatches. Subjects who do not experience pain relief after dosing will be encouraged but not required to wait at least 1.5 hours before using rescue medication. [REDACTED]

Test Naproxen Sodium 220 mg Tablet


Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

After completion of all study assessments, subjects will be discharged from the study site. Subjects will be interviewed by telephone to follow up on appropriate postsurgical medical care and changes in their health, including any emergent or existing AEs. The interview will occur between Day 6 – 10 of the study.

**Figure 1: Study Design**




## 8.2. End of Study for Each Subject

End of Study for each subject is defined as the follow-up phone call or early termination. End of Study procedures are stated in the Schedule of Activities. For subjects whose participation is discontinued during this study, end of study evaluations will be completed as soon as possible after discontinuation.

## 8.3. Sponsor Discontinuation Criteria

Premature termination of this clinical study may occur because of a regulatory authority decision, change in opinion of the IRB/IEC, drug safety problems, or at the discretion of the Sponsor. In addition, the Sponsor retains the right to discontinue development of this investigational compound at any time.

If a study is prematurely terminated or discontinued, the Sponsor will promptly notify the Investigator. After notification, the investigator must contact all participating subjects within



Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

two weeks. All study materials must be collected and all CRFs and electronic source documents completed to the greatest extent possible.

**COMPANY CONFIDENTIAL**

## **9. STUDY POPULATION**

### **9.1. Subject Eligibility Criteria**

This clinical study can fulfill its objectives only if appropriate subjects are enrolled. The following eligibility criteria are designed to select subjects for whom protocol treatment is considered appropriate. All relevant medical and non-medical conditions should be taken into consideration when deciding whether this protocol is suitable for a particular subject. No waivers to inclusion or exclusion criteria will be permitted.

#### **9.1.1. Subject Inclusion Criteria**

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

1. Males or females who are 17 to 50 years of age (inclusive) at the time of screening;
2. If female and of childbearing potential have a negative urine pregnancy at screening and at baseline;
3. Weigh 100 pounds or greater and have a body mass index (BMI) of 17.5 to 30.4 (inclusive) at screening;
4. Have undergone dental extraction of three or four third molars. Maxillary third molars may be removed regardless of impaction level. Supernumerary teeth may also be removed. The mandibular extractions must meet one of the following scenarios (and must not result in a trauma rating of 'severe' on a mild, moderate, or severe scale):
  - two full bony impactions
  - two partial bony impactions
  - one full bony impaction in combination with one partial bony impaction;
5. Indicate at least moderate pain on a categorical scale ranging from (0) none, (1) mild, (2) moderate, or (3) severe AND at least a score of 5 on the 11-point (0-10) pain intensity numerical rating scale (PI-NRS) at baseline within 4.5 hours of the last stitch from oral surgery;
6. Are able to comprehend and follow the requirements of the study (including pre-surgical instructions provided by the site and availability on scheduled visit dates) based upon research site personnel's assessment;
7. Provide written informed consent; or for subjects who are below the age of legal consent, parent or legally authorized representative provides written informed consent and the subject provides written assent;

**COMPANY CONFIDENTIAL**

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

8. Females of childbearing potential and males agree to the contraceptive requirements as outlined in section 9.3.4 and 9.3.5;
9. Are willing for this to be the only investigational product used during the study;
10. Have a negative urine drug screen at screening, and on day of surgical procedure.

#### **9.1.2. Exclusion Criteria**

Subjects will be excluded if they:

1. Are female and are pregnant, breastfeeding or currently trying to become pregnant;
2. Are male with a pregnant partner or a partner who is currently trying to become pregnant;
3. Have a known allergy or hypersensitivity to naproxen or other NSAIDs, including aspirin, or to acetaminophen, hydrocodone or other opioids;
4. Presence or history of major medical condition that in the investigator's opinion may jeopardize the subject's safety or well-being (e.g. hepatic, renal, pancreatic, gastrointestinal, cardiovascular, cerebrovascular, or thyroid diseases as well as a history of head injury or seizures, history of respiratory depression or lung problems such as but not limited to asthma or chronic obstructive pulmonary disease, psychiatric disorders, problems urinating, a history of blockage or narrowing of the stomach or intestines, uncontrolled hypertension indicated as systolic blood pressure  $\geq 160$  mm Hg or diastolic blood pressure  $\geq 100$  mm Hg, or uncontrolled diabetes in the last 6 months) or the integrity of the study;
5. Are not able to swallow whole large tablets or capsules;
6. Routinely use oral analgesics  $\geq 5$  times per week;
7. Have a history of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the investigator site staff, in the last 5 years. Heavy drinking is defined as the use of more than 4 standard drinks daily or more than 14 drinks a week for men, and more than 3 standard drinks daily or more than 7 standard drinks in a week for women. Standard drink refers to 14 g (0.6 oz.) of pure alcohol, which is approximately 12 oz. of beer, 8 oz. of malt liquor, 5 oz. of wine, 1.5 oz. or "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey);
8. Have a history of endoscopically documented peptic ulcer disease or bleeding disorder in the last 2 years;

**COMPANY CONFIDENTIAL**

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

9. Used oral OTC or prescription products (except contraceptive medications and those required for use during the oral surgical procedure), within 5 half-lives before the oral surgical procedure;
10. Used vitamins, dietary or herbal supplements within 5 days before the oral surgical procedure;
11. Used any immunosuppressive drugs, corticosteroids (except for topical corticosteroids), or injectable or oral anticoagulants (e.g., heparin, Lovenox, Xarelto, Eliquis, Pradaxa, Coumadin, Miradon) within 2 weeks of screening;
12. Used alcohol within 3 days before the oral surgical procedure;
13. Consumed methylxanthine-containing products (e.g., chocolate bars or chocolate beverages, coffee, tea, cola or caffeinated energy drinks), tobacco, or nicotine containing products (e.g., cigarettes, cigars, nicotine replacement therapies) < 12 hours before the oral surgical procedure;
14. Use of monoamine oxidase inhibitors within 14 days prior to surgery;
15. Has a positive test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV);
16. Participated in any interventional clinical trials within 30 days before screening;
17. Are related to those persons involved directly or indirectly with the conduct of this study (i.e., PI, sub investigators, study coordinators, other site personnel, employees of Johnson & Johnson subsidiaries, contractors of Johnson & Johnson, and the families of each).

## **9.2. Subject Withdrawal/Termination Criteria**

Subjects have the right to withdraw from the study at any time for any reason without compromising their rights to receive further treatment. The Investigator and/or the Sponsor may terminate a subject from investigational treatment and/or study follow-up in the event of any of the following:

- Medical reasons considered significant by the subject, Investigator and/or the Sponsor, which may include, an Adverse Event (AE), intercurrent illness or medical reasons unrelated to the study
- Nonmedical reasons (e.g., subject request or noncompliance with the treatment procedure as determined by the Investigator, the Sponsor and/or subject)
- Pregnancy

**COMPANY CONFIDENTIAL**

- Serious eligibility or on-study violation of the protocol
- Administrative or other reasons (e.g., lost to follow-up, non-compliance)

Should a subject decide to withdraw from the study at any point, all efforts should be made to complete all end of study assessments. In case of questions surrounding the circumstances that a subject needs to be withdrawn from the study (e.g., protocol deviation), the Sponsor, or the Sponsor representative should be consulted. The reason for withdrawal should be documented in the subject's source document and in the Subject Disposition CRF.

If a subject is lost to follow-up, every reasonable effort must be made by the study site personnel to contact the subject and determine the reason for discontinuation/withdrawal before considering the subject to be lost to follow-up. Such efforts should include repeated telephone calls, certified letters as described in section [11.6](#). The measures taken to follow up must be documented.

### **9.3. Life Style Guidelines**

#### **9.3.1. Meals and Dietary Restrictions**

Only clear, non-caffeinated liquids may be consumed from the time of surgery until two hours following administration of the investigational product. After two hours, subjects may consume soft foods consistent with having dental surgery.

#### **9.3.2. Alcohol, Caffeine and Tobacco Consumption / Restrictions**

Use of alcoholic beverages within three days before the oral surgical procedure and during the study is prohibited. In addition, subjects must refrain from the use of any methylxanthine-containing products (e.g., chocolate bars or beverages, coffee, tea, colas, or caffeinated energy drinks) and tobacco or nicotine containing products (e.g., cigarettes, cigars, nicotine replacement therapies) within 12 hours before surgery and during the study while confined at the site.

#### **9.3.3. Physical Activity Requirements / Restrictions**

Walking at a normal pace will be permitted. Subjects will remain sitting upright or semi-reclining for dosing and at least 4 hours immediately following treatment administration, except for short durations to use the restroom.

#### **9.3.4. Contraception for Females**

Female subjects with reproductive potential must agree to practice a medically acceptable form of birth control throughout the study and for 30 days following the last dose of investigational product, whichever is later. Females must have used such birth control for at least three months prior to the Baseline visit.



Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

Medically acceptable forms of birth control that may be used by the subject and/or his/her partner include:

- Established use of hormonal methods of contraception (oral, injected, implanted, patch or vaginal ring). Sexually active female subjects (or female partners of male subjects) who use hormonal contraception must have used a stable dose for at least 30 days before surgery. If hormonal contraception has been used for less than 30 days or if the dose has changed within the past 30 days, subjects must agree to also use a barrier method during the study and at least 30 days after taking the investigational product.
- Barrier methods of contraception with spermicide: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/ film/ cream/ suppository;
- Intrauterine device (IUD) or intrauterine system (IUS);
- Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal occlusion, hysterectomy, bilateral salpingectomy);
- Abstinence from heterosexual intercourse: When this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Female subjects are not considered of childbearing potential if they meet at least one of the following criteria:


- Had a hysterectomy and/or bilateral oophorectomy at least 6 months prior to product administration;
- Had sterilization surgery (e.g., hysteroscopic sterilization/tubal implants or tubal ligation) at least 6 months prior to screening; tubal implants must have been confirmed effective by medical assessment as reported by the subject;
- Are postmenopausal (i.e., amenorrheic for at least 12 consecutive months, without an alternative medical cause, prior screening).

### **9.3.5. Contraception for Males**

Male participants will be informed about potential risks of the study medication for embryos and fetuses.

Male subjects are instructed to prevent their partner from becoming pregnant from the first dose of study medication until at least 30 days after the last dose of study drug. Information about effective means of birth control (hormonal contraception, intrauterine devices,

**COMPANY CONFIDENTIAL**



Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

vasectomy, sexual abstinence) will be provided, and discussed as appropriate with individual subjects.

**COMPANY CONFIDENTIAL**

## 10. STUDY INTERVENTION

### 10.1. Description and Administration

A description of the test naproxen, reference naproxen and placebo investigational products are provided in [Table 4](#).

**Table 4: Investigational Product**

Product	Test NPX (440 mg)	██████ Tablets (440 mg)	██████████ Capsules (440 mg)	Placebo
Dosage Form	Tablet	Tablet	Liquid-filled Capsule	Tablet
Route of Administration	Oral	Oral	Oral	Oral
Unit Dose	220 mg	220 mg	220 mg	Not applicable
Physical Description	██████████ ████████████████████	██████████ ████████████████████	██████████████████ ██████████	██████████ ██████████████████
Manufacturer/Brand	██████████	██████████	██████████	██████████

### 10.2. Packaging and Labeling

Product will be provided in High Density Polyethylene (HDPE) bottles. Each bottle will be labeled with a single panel sponsor study label.

### 10.3. Preparation, Handling and Disposal

Investigational products and placebo will be supplied by the Sponsor in bulk containers in an unblinded manner. In order to maintain the double-blind status of the study, the site must adhere to the following general storage, dispensing, and dosing procedures:

- The site will delegate a qualified third party and back-up staff member(s) who will be responsible for dispensing and administering study medication and who will have no other direct or indirect role in the execution of this study.

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

- The Sponsor will provide a randomization schedule directly to the qualified third-party individual. The randomization schedule will be kept in a locked, secured area with access limited to only the assigned third-party individual and un-blinded monitor.
- Covered dosing cups will be used by the assigned third-party dispenser to transport the assigned investigational product from the designated dispensing room to the subject's room.

Investigational product preparation and dispensing will be performed on Day 1, following dental surgery. For subjects who meet the randomization criteria, an independent third-party dispenser will administer one of the following study treatments with up to 180 ml of water at ambient temperature to blindfolded subjects:

- a single 440-mg dose of naproxen sodium as two Test NPX 220 mg tablets
- a single 440-mg dose of naproxen sodium as two commercial [REDACTED] 220 mg tablets
- a single 440-mg dose of naproxen sodium as two commercial [REDACTED] 220 mg capsules, or
- a single dose of two placebo tablets

Baseline pain assessments and drug administration will be completed in the subject's room. The third-party dispenser will prepare study medication for each subject in a designated dispensing room. Study medication will be dispensed at the time that the subject's pain level is determined to be eligible by verbal assessment, just prior to the completion of the baseline categorical pain severity scale and the baseline 11-point [0-10] pain intensity numerical rating scale [PI-NRS]. The study coordinator will communicate the subject's pain severity and gender to the dispenser. The dispenser will assign the next available randomization number from the appropriate stratum. The dispenser will dispense the appropriate study treatment from the appropriate bulk supply containers into an individual dosing cup. The double-blind label with the same randomization number will be affixed to the dosing cup and the tear-off portion of the label will be attached to the patient's source documents. The third-party dispenser will complete the study drug dispensing record. The study drug dispensing record will remain in a secure and locked area, with access limited to the unblinded third-party dispenser, back-up staff member, and un-blinded monitor. A second individual, with no other study involvement, will witness the preparation and dispensing process. No other study personnel will be present in the designated dispensing room at the time of study drug dispensing. The dispenser will ensure the dosing cup containing the randomized study treatment is covered prior to exiting the dispensing room.

The third-party dispenser will inform the blinded study coordinator once the study drug is dispensed and is ready to be administered to the subject. Following completion of the baseline categorical pain severity scale and baseline pain intensity numerical rating scale, the study coordinator will blindfold the subject and then exit the subject's room to inform the dispenser that the pain assessments are completed and confirm that the pain severity has not changed from the verbal assessment used to determine the appropriate randomization, and

**COMPANY CONFIDENTIAL**

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

that the pain intensity numerical rating scale score qualifies the subject for randomization. If the baseline categorical pain severity has changed, new study drug from the corresponding pain stratum will be prepared and the randomization number and study medication corresponding to the original pain stratum will not be reused. The dispenser will deliver the study drug from the designated dispensing room to the subject's room in a covered dosing cup to ensure no other individual will be able to see the study drug in the bottle. No other study personnel, other than the third-party witness, will be present in the subject's room at the time of dosing.

After entering the blindfolded subject's room and while the subject is sitting up, the dispenser will hand the dosing cup containing the study treatment to the blindfolded subject and instruct the subject to empty the contents of the dosing cup directly into their mouth and then swallow the study medication immediately with up to 180 ml of water at ambient temperature. The dispenser will inspect the subject's oral cavity to ensure that the study treatment was swallowed. The time at which the subject swallows the study medication will be recorded as Time 0. Study drug will be administered to the subject within 5 minutes of the completion of the baseline pain assessments.

If a subject vomits after dosing, the subject will not be re-dosed but will remain in the study.

At the end of the study, the Sponsor will provide instructions as to disposition of any unused investigational product. If the Sponsor authorizes destruction at the study site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by the Sponsor. Destruction must be adequately documented.

#### **10.4. Storage and Accountability**

The investigator, or an approved representative, e.g., pharmacist, will ensure that all investigational product is stored in a secured area, at room temperature, 68 °F to 77 °F (20 °C to 25 °C) and in accordance with applicable regulatory requirements.

The investigator, or assigned representative, must maintain adequate records documenting the receipt, use, loss, or other disposition of the investigational product on the Investigational Product Accountability Log supplied by the Sponsor. The log must identify the investigational product and randomization number, and account for its disposition on a subject-by-subject basis, including specific dates administered and quantities. The log must be signed by the individual who dispensed the investigational product, and copies must be provided to the Sponsor. All Investigational Product and Investigational Product Logs are kept together in a secure, double-locked location with access only allowed to the third-party person(nel), back-up staff member and un-blinded monitor. The study site must maintain accurate and adequate records including shipment receipt and return of unused investigational product shipments.

**COMPANY CONFIDENTIAL**

## **10.5. Randomization/Treatment Allocation**

The randomization schedule will be generated by the Sponsor to ensure treatment blinding. The site will keep the randomization schedule in a locked, secured area with access limited to only the assigned third-party person(nel), back-up staff member, and un-blinded monitor. After meeting the appropriate post-surgery criteria, subjects will be randomized to receive one of four treatments (Test NPX 440 mg, [REDACTED] tablet 440 mg, [REDACTED] 440 mg or placebo) in a 3:3:3:1 ratio. Subjects will be stratified by gender and baseline pain (moderate or severe). For subjects with moderate baseline pain, randomization numbers will be assigned to subjects in sequential order starting with the lowest available number within the appropriate gender stratum. Similarly, for subjects with severe baseline pain intensity, subjects will be assigned in sequential order starting with the highest available number in the appropriate gender stratum.

## **10.6. Blinding and Unblinding**

If, in the opinion of the Investigator, it is necessary to break the treatment code for safety reasons and circumstances allow, the Investigator will first contact the Designated Physician Representative or designee for consultation about breaking the study blind. If there is a medical emergency and the Investigator deems it necessary to know the subject's study treatment urgently for the subject's proper medical care, the Investigator may break the treatment code immediately, and then contact the Designated Physician Representative or designee as soon as possible afterward.

In the event of a medical emergency that necessitates breaking the code, the third-party person(nel) will be permitted to inform the Investigator what study drug the subject was given.

When the blind is broken, the Investigator will notify the Sponsor within 24 hours after determining that it is necessary to unblind the treatment assignment and document the reason and date of the unblinding. The event will also be recorded in the CRF and in the source document. Any AE or (Serious Adverse Event) SAE associated with breaking the blind must be recorded and reported as specified in this protocol.

Once the treatment is unblinded, the subject must be discontinued from the study and followed until the event is resolved. The rationale, date, time, and attempts to contact the Sponsor must be documented in the source document. The study site should take the necessary measures to maintain the treatment blind throughout the study and prevent any unintended or premature unblinding.

## **10.7. Treatment Compliance**

All subjects randomized to treatment in this study will be in compliance if they take the dose of study medication.

## **10.8. Previous and Concomitant Medications**

Medications and other treatments that are taken from 30 days prior to screening until the end of the 12-hour assessment period will be recorded in the source documents and CRF.

Medications and other treatments taken after the 12-hour assessment period through the follow-up interview will be captured on the source documents and only those taken for or associated with an AE will also be recorded in the CRF.

### **10.8.1. Permitted Therapies**

Female subjects taking hormonal contraceptives will be instructed to continue before, during, and after the study as per protocol. All subjects will be permitted a short-acting local anesthetic, lidocaine with or without epinephrine, and/or nitrous oxide during dental surgery. Topical benzocaine is also allowed.

### **10.8.2. Prohibited Therapies**

Long-acting anesthetics are prohibited during the dental surgery. Other medications prohibited before entry into the study are listed under Exclusion Criteria.

The use of any oral OTC or prescription products (except contraceptive medications and those required for use during oral surgical procedure such as short-acting local anesthetics) are prohibited within 5 half-lives before the surgical procedure and during the on-site portion of the study. In addition, vitamins, dietary or herbal supplements are prohibited within 5 days before the oral surgical procedure and during the on-site portion of the study.

## **10.9. Rescue Therapy**

Subjects will be encouraged, but not required, to wait at least 1.5 hours after investigational product dosing before using the rescue medicine, hydrocodone bitartrate 5 mg / acetaminophen 325 mg, if the severity of the subject's pain increases to an intolerable level. Hydrocodone bitartrate 5 mg / acetaminophen 325 mg tablets will be used according to its product labeling. Use of rescue medicine will be recorded in the source document and CRF. Once rescue medicine has been administered, the stopwatch(s) will be collected from the subject. No stopwatch data will be recorded after use of rescue medication; [REDACTED]

## **10.10. Product Quality Complaints**

A Product Quality Complaint (PQC) is any written, electronic, or oral communication, query, observation, or issue related to the identity, quality, durability, reliability, safety, efficacy or performance of investigational supplies. Any PQC discovered during the initial inventory should follow the instructions provided on the receipt letter; no PQC form should be filed for issues identified when opening or unpacking a shipment. Subsequently, any observation of a PQC requires immediate notification to the Sponsor's un-blinded Study Manager via a

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

completed PQC form and telephone call. The un-blinded Study Manager will then send the completed PQC form to the Clinical Supply Manager. During the PQC process, the un-blinded Study Manager can assist or answer any questions the site may have. If a photograph is required to better understand the nature of the PQC, the site should send the photograph directly to the un-blinded Study Manager who will then forward it to the Clinical Supply Manager.

**COMPANY CONFIDENTIAL**



## **11. STUDY PROCEDURES**

### **11.1. Overview**

The Schedule of Activities/Study Flow Chart ([Section 2](#)) summarizes dose administration and the timing and frequency of safety and efficacy procedures and measurements. In the event of abnormal safety findings during the conduct of the study, the attending physician may request additional safety evaluations, either immediately or subsequently at a frequency considered appropriate.

### **11.2. Screening Visit**

Informed consent will be obtained from the subjects before any study related assessments are conducted.

- Inclusion and exclusion criteria
- Demography
- Collection of age
- Significant medical history – the condition, diagnosis, or surgical procedure
- History of medication and other treatments (within 30 days prior to screening)
- Vital signs: resting blood pressure, heart rate, respiratory rate, oral temperature
- Height, weight and BMI assessment
- A serum sample will be collected to test for HIV antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV)
- Urine drug screen test
- Urine pregnancy test on females with childbearing potential

Subjects who meet all study entry requirements per the inclusion/exclusion criteria will be scheduled for the dental procedure within 30 days after Screening.

### **11.3. Baseline Visit (Day of Surgery)**

The following will be re-evaluated prior to the surgical procedure, and the evaluations will be recorded in the source documents and the CRF. For data collected on both Screening and Baseline Visits, only the data collected at Baseline will be recorded on the CRF.

- Inclusion and exclusion criteria
- Any changes to medical and surgical history

Test Naproxen Sodium 220 mg Tablet  
Protocol: CCSPAA000457  
Version 1: 11 May 2018  
Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

- Any changes to prior and concomitant therapies
- Vital signs: resting blood pressure, heart rate, respiratory rate, oral temperature
- Urine drug screen test
- Urine pregnancy test on females with childbearing potential

A negative urine drug screen and urine pregnancy test (for women of childbearing potential) must be obtained on the same day as the surgical procedure.

#### **11.4. Randomization**

After the dental procedure, subjects will be asked to rest quietly at the study center until they experience both post-surgical pain of at least moderate pain on a categorical scale ranging from (0) none to (3) severe and at least a score of 5 on the 11-point (0-10) PI-NRS within 4.5 hours of the last stitch during oral surgery. Subjects who did not meet these criteria will be considered a screen failure.

Randomization numbers will be assigned to subjects in sequential order starting with the lowest available number within the appropriate gender stratum for subjects with moderate baseline pain and starting with the highest available number in the appropriate gender stratum for subjects with severe baseline pain intensity. Randomized subjects will receive their dose of investigational product, which will be considered time 0. The administration of investigational product should occur as described in Section 10.3. Site staff will inspect the subject's oral cavity to ensure that the investigational product was swallowed.

#### **11.5. Post dose Assessments**

Two stopwatches labeled as perceptible and as meaningful will be used to measure "perceptible pain relief" and "meaningful pain relief", respectively. The face of each stopwatch will be covered to prevent the subject from seeing the running clock. Upon dosing, the investigator or the designated site staff will start both stopwatches at the same time. Subjects will only be given the second stopwatch after they stop the first one.

Site personnel will instruct "I would like you to stop the first stopwatch (perceptible) when you first begin to feel any pain relieving effect whatsoever of the drug, that is, when you first feel any pain relief. This does not necessarily mean you feel completely better, although you might, but when you first feel any difference in the pain you have now. As soon as you stop the stopwatch please press your call light to notify the study coordinator. I would like you to stop the second stopwatch (meaningful) when you have meaningful pain relief, that is, when the relief from the starting pain is meaningful to you. As soon as you stop the stopwatch, please press your call light to notify the study coordinator." Upon dosing, the investigator or the designated site staff will start both stopwatches at the same time. Once the stopwatch has been stopped, the investigator or designated study staff will retrieve the stopwatch and record the time in the source documents and CRF. [REDACTED]

**COMPANY CONFIDENTIAL**

([APPENDIX 1](#))

Subjects who use rescue therapy will continue in the study ([APPENDIX 2](#)).

### **11.6. Follow-Up Phone call**

Subjects will be interviewed by telephone to follow up on appropriate postsurgical medical care and changes in their health, including any emergent or existing AEs. The interview will occur between Day 6 – 10. At least three attempts should be made to contact the subject by phone. If the subject cannot be contacted by phone by Day 10, then a certified letter should be mailed to the subject. Every effort will be made by the investigator or designated study staff to adhere to the schedule. Additional postsurgical medicines (e.g., antibiotics or analgesic prescriptions) or therapies (e.g., ice packs) that are taken after the 12-hour [REDACTED] will be recorded on the subject's source documents, but not in the CRF; however concomitant medications and other treatments taken for or associated with an AE will be recorded on the CRF and the source documents. Emergent or existing AEs will be recorded in both the source documents and CRF.

## 12. ASSESSMENTS

### 12.1. Efficacy Assessments

[REDACTED]. Evaluations will include the following parameters:

- Pain intensity
  - Four-point categorical scale collected at baseline: (0) no pain; (1) mild pain; (2) moderate pain; (3) severe pain
  - 0-10 PI-NRS collected at baseline [REDACTED]
- [REDACTED]
- Time to perceptible pain relief – recorded using stopwatch perceptible
- Time to confirmed perceptible pain relief is defined as the time to perceptible pain relief, provided that the subject subsequently stopped the second stopwatch indicating meaningful pain relief.
- [REDACTED]
- [REDACTED]
- [REDACTED]

### 12.2. Safety Assessments

Safety will be monitored via AE reporting. If an AE is reported, the subject will be asked to elaborate on the nature of the event. The investigator or designated study staff will evaluate and record according to the AE Reporting section of the protocol.

Normal consequences of dental surgery (e.g., pain, swelling, bruising) are not considered AEs unless the investigator believes the condition worsened or was aggravated following study drug therapy.

### **12.2.1. Physical Examination**

Height and weight measurements will be collected at screening and BMI will be calculated.

### **12.2.2. Vital Signs**

Vital signs will be collected at screening and baseline. All vital signs (blood pressure, pulse, respiratory rate, and oral body temperature) will be collected after at least 5 minutes of rest in a supine or semi-reclining position in a quiet setting without distractions (e.g., television, cell phones). Systolic and diastolic blood pressure and pulse rate measurements will be assessed with a completely automated device, consisting of an inflatable cuff and an oscillatory detection system. All values will be registered on an automated recorder so that measurements are observer independent. Manual techniques will be used only if an automated device has malfunctioned. Respiratory rate will be measured over at least 30 seconds. Oral body temperature will be measured using a Sponsor-approved standard method. Abnormal vital signs collected at screening and baseline will be assessed by the medically qualified investigator to confirm that the subject is medically suitable for study participation.

### **12.2.3. Clinical Laboratory Tests**

Females of childbearing potential will have a urine pregnancy at screening visit and at baseline. Serology will be performed at screening and will include HIV antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV). A urine drug screen will also be performed at screening and baseline. The minimum requirements for urine drug testing include cocaine, tetrahydrocannabinol, opioids (e.g., buprenorphine, oxycodone, methadone, and morphine), benzodiazepines, and amphetamines.

## **13. ADVERSE EVENTS**

Timely, accurate, and complete reporting of safety information from clinical studies are crucial for the protection of subjects, Investigators, and the Sponsor, and are mandated by regulatory agencies worldwide. All observed or volunteered AEs regardless of suspected causal relationship to the Investigational Product(IP) will be reported as described in the following sections. For all AEs, the Investigator or medically qualified individual (MD/DO/DMD/DDS) must pursue and obtain adequate information to make the appropriate assessments.

### **13.1. Definitions**

#### **13.1.1. Definition of Adverse Event**

An AE is any untoward medical occurrence that occurs in a subject after they have signed an informed consent for a study. The event does not need to have a suspected causal relationship with the IP. Therefore, an AE can be any unfavorable and unintended sign, symptom, disease or injury temporally associated with the subject's participation in the study. Examples of AEs include, but are not limited to:

- Abnormal test findings,
- Clinically important signs and symptoms,
- Changes in physical examination findings,
- Hypersensitivity, and
- Progression/worsening of underlying disease.

Additionally, they may include the signs or symptoms resulting from:

- Overdose,
- Withdrawal,
- Abuse,
- Drug misuse,
- Drug interactions,
- Medication errors,
- Product dependency,
- Exposure *in utero*, and
- Study related procedure

**COMPANY CONFIDENTIAL**

### **13.1.1.1. Abnormal Test Findings**

The criteria for determining whether an abnormal objective test finding should be reported as an AE are as follows:

- Test result is associated with accompanying symptoms, and/or
- Test result requires additional diagnostic testing or medical/surgical intervention beyond ordering a repeat (confirmatory) test, and/or
- Test result leads to a discontinuation from the study, significant additional concomitant treatment, or other therapy, and/or
- Test result is considered to be an AE by the medically qualified investigator or designee or the Sponsor.

Merely repeating an abnormal test, in the absence of any of the above conditions, does not constitute an AE. Any abnormal test result that is determined to be an error does not require reporting as an AE.

### **13.1.2. Definition of Serious Adverse Events (SAE) for Drugs**

An AE or suspected adverse reaction is considered “serious” for a drug study if, in the view of either the medically qualified investigator or designee (MD/DO/DMD/DDS) or the Sponsor, it results in any of the following outcomes:

- Results in death,
- Is life-threatening (immediate risk of death),
- Requires inpatient hospitalization or prolongation of existing hospitalization,
- Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions,
- Results in congenital anomaly/birth defect,
- Is considered medically significant (medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not result in death, be life-threatening or require hospitalization but may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the other outcomes listed above). Examples of such medical events include allergic bronchospasm requiring intensive treatment in an Emergency Room or at home, blood dyscrasia, or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse, or malignancy), or,

- Is a suspected transmission of any infectious agent via a medical product (medically significant) and should be reported as an SAE in the category ‘Other medically important conditions.’

An AE or suspected adverse reaction is considered “serious” for a device study if, in the view of either the Investigator or the Sponsor, it results in any of the following outcomes:

- Death
- Serious injury which means an injury or illness that:
  - Is life-threatening (immediate risk of death),
  - Results in permanent impairment of a body function or permanent damage to a body structure, or
  - Requires inpatient hospitalization or prolongation of existing hospitalization,
  - Necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure; permanent means irreversible impairment or damage to a body structure or function, excluding trivial impairment or damage.
- Results in congenital anomaly/birth defect
- Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- A malfunction that the device (or similar device marketed by the same manufacturer or importer) would be likely to cause death or similar injury if the malfunction were to recur
- Any suspected transmission of any infectious agent via a medicinal product (medically significant).

#### **13.1.2.1. Hospitalization**

AEs reported from clinical studies associated with hospitalization or prolonging hospitalization are considered serious. Any initial admission (even if less than 24 hours) to a healthcare facility meets these criteria. Admission also includes transfer within the hospital to an acute/intensive care unit (e.g., from the psychiatric wing to a medical floor, medical floor to a coronary care unit, neurological floor to a tuberculosis unit). Hospitalization does not include the following:

- Rehabilitation facilities,
- Hospice facilities,
- Respite care (e.g., caregiver relief),



- Skilled nursing facilities,
- Nursing homes,
- Emergency room visits (unless the reason for the emergency room visit meets one of the other outcomes in the definition of serious), and/or
- Same day surgeries (as outpatient/same day/ambulatory procedures),
- Hospitalization or prolongation of hospitalization in the absence of a precipitating, clinical AE is not in itself an SAE. Examples include:
  - Admission for treatment of a pre-existing condition not associated with the development of a new AE or with a worsening of the pre-existing condition (e.g., for work-up of persistent pre-treatment lab abnormality),
  - Social admission (e.g., subject has no place to sleep),
  - Administrative admission (e.g., for yearly physical exam),
  - Protocol-specified admission during a clinical study (e.g., for a procedure required by the study protocol),
  - Optional admission not associated with a precipitating clinical AE (e.g., or elective cosmetic surgery),

Pre-planned treatments or surgical procedures should be noted in the baseline documentation for the entire protocol and/or for the individual subject.

- Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, should not be reported as AEs. However, the medical condition for which the procedure was performed should be reported if it meets the definition of an AE. For example, an acute appendicitis that begins during the AE reporting period should be reported as the AE and the resulting appendectomy should be recorded as treatment of the AE.

## **13.2. Adverse Event Assessments**

Sufficient information should be obtained for each AE to allow the Investigator or medically qualified individual to make assessments as described below.

### **13.2.1. Severity Assessment**

The severity of AEs will be assessed by the medically qualified Investigator or designee using the following general categorical descriptors:

MILD: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with the subject's usual function or normal everyday activities.

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

**MODERATE:** Sufficient discomfort is present to cause interference to some extent with the subject's usual function or normal everyday activity.

**SEVERE:** Extreme distress, causing significant impairment of functioning or incapacitation; interferes significantly with subject's usual function; prevents normal everyday activities.

Note the distinction between the severity and the seriousness of an AE. A severe event is not necessarily a serious event. For example, a headache may be severe (interferes significantly with the subject's usual function) but would not be classified as serious unless it met one of the criteria for SAEs listed above.

### **13.2.2. Causality Assessment**

The medically qualified Investigator's assessment of causality to IP (i.e., relationship to IP) must be provided for all AEs (serious and non-serious). The causality assessment is the determination of whether there exists a reasonable possibility that the IP caused or contributed to an AE.

- Not Related - An AE that is not related to the use of the drug
- Doubtful - An AE for which an alternative explanation is more likely, e.g., concomitant drug(s), concomitant disease(s), or the relationship in time suggests that a causal relationship to IP is unlikely.
- Possible - An AE that might be due to the use of the drug. An alternative explanation, e.g., concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, the causal relationship to IP cannot be excluded.
- Probable - An AE that might be due to the use of the drug. The relationship in time is suggestive (e.g., confirmed by dechallenge) and an alternative explanation is less likely, e.g., concomitant drug(s), concomitant disease(s).
- Very Likely - An AE that is listed as a possible adverse reaction and cannot be reasonably explained by an alternative explanation, e.g., concomitant drug(s), concomitant disease(s). The relationship in time is very suggestive (e.g., it is confirmed by dechallenge and rechallenge) for a causal relationship to the drug.

Any AE that occurs after the informed consent has been signed, until first usage of investigational product, will be considered non-treatment emergent and cannot (by virtue of time of occurrence) have a causal relationship with the IP.

If the Investigator determines an AE is associated with study procedures, the Investigator must record this suspected causal relationship in the source documents and the SAE form, as appropriate, and report such an assessment in accordance with the SAE reporting requirements, if applicable.

**COMPANY CONFIDENTIAL**

### **13.2.3. Resolution**

The medically qualified Investigator or designee will be required to assess the outcome of the AE for IP as one of the following:

- Resolved,
- Not Resolved,
- Fatal,
- Resolved with sequelae,
- Resolving, or
- Unknown.

Any causally-related AEs that are not resolved upon completion of the last study visit will be followed up by the study staff until the event or its sequelae resolve or stabilized at a level acceptable to the medically qualified Investigator or designee, and recorded on the CRF. An event that is assessed as resolved with sequelae or resolving indicates that the subject has stabilized to a level acceptable to the medically qualified Investigator or designee and has concurrence by the Sponsor.

## **13.3. Adverse Event Reporting**

### **13.3.1. Time Period**

All AEs, whether serious or non-serious, will be collected starting from the time a subject signs and dates an informed consent until the completion of the subject's last study-related procedure, which may include contact for follow-up of safety. Spontaneous reports of serious AEs will be collected through and including 30 calendar days after subject's last dose of IP. Any SAE occurring any time after the reporting period must be promptly reported if a causal relationship to study product is suspected.

### **13.3.2. Process for Reporting**

The Investigator is to report all AEs whether directly observed or spontaneously reported by the study subject. In addition, each study subject will be questioned in general about any AEs.

All AEs, serious or non-serious, will be recorded on the source documents; e.g., written documentation, electronic medical records, subject diaries or journals. AEs will be entered into CRFs for screen failure subjects as well as randomized subjects. AEs should be reported using concise medical terminology on the CRFs. Each AE is to be assessed to determine if it meets the criteria for an SAE. If an SAE occurs, expedited reporting is required.

### **13.3.2.1. Serious Adverse Event Reporting**

A Clinical SAE Report Form must also be completed if the event is considered to be serious. Where the same data are collected, the Clinical SAE Report Form and the AE CRF must be completed in a consistent manner. For example, the same AE term should be used on both forms.

If an SAE occurs, the Sponsor or designee must be notified by telephone, email or fax immediately upon awareness of the event by the Investigator's site and the SAE documented on the source document. Within 24 hours of the Investigator site's awareness of the event, the study site must send the Sponsor the Clinical SAE Report Form (via a secure e-mail or fax). This timeframe also applies to additional new information (follow-up) on previously reported SAEs as well as to the initial and follow-up reporting of Exposure In Utero (EIU) cases. In the rare event that the Investigator's site does not become aware of the occurrence of an SAE immediately (e.g., in a telephone contact, in a subject diary or journal, or if an outpatient study subject initially seeks treatment elsewhere), the Investigator's site is to report the event immediately after learning of it as described, and document the date and time of the study site's first awareness of the AE in the subject's file.

For all SAEs, the Investigator is obligated to pursue and provide information to the Sponsor in accordance with the timeframes for reporting specified above. In addition, an Investigator may be requested by the Sponsor to obtain specific additional follow-up information in an expedited fashion. This information may be more detailed than that captured on the AE CRF. In general, this will include a description of the AE in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Information on other possible causes of the event, such as concomitant medications and illnesses must be provided. In the case of a subject death, a summary of available autopsy findings (if available) and death certificate should be collected if permission is obtained from the subject's family. For a hospitalization, a copy of the hospital discharge summary should be requested. If obtained, these documents (with subject's personal identifiers redacted) should be submitted as soon as possible to the Sponsor or its designated representative.

Appropriate SAE forms will be provided to the study site at the initiation of the study.

### **13.3.2.2. Contacts for Serious Adverse Event Reporting**

Study Contacts for reporting can be found on the Study Contact List kept in the Site Master File.

All nonserious AEs are to be reported on the AE CRFs and will be submitted to the Sponsor.

### **13.4. Suspected Unexpected Serious Adverse Reaction**

If the Sponsor judges an SAE to be a Suspected Unexpected Serious Adverse Reaction (SUSAR), the Sponsor will report it to the Regulatory Authority(ies) and the Investigator (or Sponsor) must report to the IRB/IEC as required and in accordance with the Sponsor's standard operating procedures for safety reporting.

### **13.5. Special Situations**

Special Situations are safety events that may not meet the definition of an AE; however, from a policy perspective, they are treated in the same manner as AE and recorded in the source document and CRF. Examples include:

- Pregnancy exposure (maternal and paternal) to a J&J product, see next section;
- Off-label use of a J&J product. *Note: Off-label use of a product without an associated AE should be collected only when it is specifically and voluntarily brought to the attention of the company in an unsolicited manner by a reporter (e.g., Patient or HCP), or data obtained from databases where off-label use may be systematically collected (e.g., reimbursement database in US), and in accordance with local procedure in compliance with local laws and regulations.*
- Overdose of a J&J product;
- Exposure to a J&J product from breastfeeding;
- Suspected abuse/misuse of a J&J product;
- Inadvertent, accidental exposure, or occupational exposure to a J&J product;
- For marketed products, any failure of expected pharmacological/therapeutic action (i.e., lack of effect) of a J&J product. Lack of effect/Lack of efficacy defined as any failure that a product did not achieve expected pharmacological action/therapeutic benefit when used in accordance with the Reference Safety Information or equivalent. In the context of complaint intake, lack of effect shall be reported if there is specific evidence that the reporter did not think the product achieved expected pharmacological action/therapeutic benefit evidenced by statements such as or similar to “the product did not work/perform as expected”;
- Medication error involving a J&J product (with or without patient exposure to the J&J product, e.g., product name confusion); or
- Unexpected therapeutic or clinical benefit from use of a J&J product.

#### **13.5.1. Exposure In Utero**

An *exposure in utero* (EIU) occurs if:

COMPANY CONFIDENTIAL

1. A woman is exposed to the IP at any time between her last menses prior to conception through the delivery of the baby.
2. There is a possibility of intrauterine exposure to IP via semen from the male partner who is taking/using the IP at the time of conception, thereby possibly exposing the fetus to the product.

If an EIU occurs, the Investigator or designee should inform the Sponsor immediately. This must be done irrespective of whether an AE has occurred. The site must complete a Pregnancy Notification and Update Form and send it securely to the Sponsor within 24 hours of the site's awareness. The information submitted should include the anticipated date of delivery (see below for information related to induced termination of pregnancy). This reporting requirements include environmental exposure to the IP in a pregnant woman (e.g., a nurse reports that she is pregnant and has been exposed to a cytotoxic product by inhalation or spillage).

Follow-up should be conducted to obtain pregnancy outcome information on all EIU reports. The Investigator will follow the pregnancy until completion or until the pregnancy terminated (i.e., induced abortion) and then notify the Sponsor of the outcome. The Investigator will provide any updated information as a follow-up using the Pregnancy Notification and Update Form, and will report the outcome on the End of Pregnancy Collection Form. The reason(s) for an induced abortion should be specified. An EIU report is not created when an ectopic pregnancy report is received since this pregnancy is not usually viable. Rather, an SAE case is created with the event of ectopic pregnancy.

The medically qualified investigator or designee (MD/DO/DMD/DDS) should follow the procedures for reporting SAEs if the outcome of the pregnancy meets the criteria for immediate classification as an SAE (i.e., spontaneous abortion, stillbirth, neonatal death, or congenital anomaly [including that in an aborted fetus, stillbirth, or neonatal death]). In the case of a live birth, the "normality" of the newborn can be assessed at the time of birth (i.e., no minimum follow-up period of a presumably normal infant is required before an End of Pregnancy Collection Form can be completed). The "normality" of an aborted fetus can be assessed by gross visual inspection, unless pre-abortion test findings are suggestive of a congenital anomaly.

Additional pregnancy outcomes that are classified as SAEs and should be reported as such include:

- "Spontaneous abortion" includes miscarriage and missed abortion.
- All neonatal deaths that occur within 1 month of birth, without regard to causality.
- Any infant death after 1 month that the Investigator assesses as possibly related to EIU to the IP.

**COMPANY CONFIDENTIAL**

## **14. STATISTICS**

The Sponsor will be responsible for the statistical analysis of study data. Detailed methodology for the statistical analysis of the data will be documented in a Statistical Analysis Plan finalized and approved prior to database lock and release of randomization codes.

### **14.1. Sample Size Determination**

A sample size of 150 per group for the active treatment arms was chosen based on pharmacokinetic/pharmacodynamics modeling and simulation using data from previous studies[3]. Based on the modeling, it was determined that 150 subjects per active treatment arm would be needed to provide 90% power to reject the null hypothesis of equal distributions for time to confirmed perceptible relief, when comparing Test NPX tablets with [REDACTED] tablets, using a two-sided test at the 0.05 significance level. A sample size of at least 50 subjects per treatment arm provides greater than 90% power to reject the null hypothesis of equal distributions for time to confirmed perceptible relief when comparing Test NPX tablet and placebo assuming median times to relief of 17 minutes for Test NPX and at least 2 hours for placebo.

#### **14.1.1. Efficacy Analyses Sets**

The primary efficacy analyses will be based on the Intent-to-Treat analysis set, which will include all randomized subjects. As a secondary analysis, the primary endpoint will be analyzed based on the per-protocol analysis set, if the per-protocol analysis set differs from the Intent-to-Treat set by at least 5% of the subjects. The per-protocol set will exclude subjects who took rescue medication within 90 minutes after dosing, vomited within 60 minutes after dosing, and those with major protocol deviations. The final per-protocol set will be determined before unblinding.

#### **14.1.2. Safety Analysis Population**

The Safety Set will include all subjects who are randomized and take investigational product.

### **14.2. Baseline and Demographics**

Baseline and demographic characteristics will be presented by treatment group for each analysis set. For continuous variables, descriptive summaries will include number of subjects, mean, standard deviation, median and range (min, max). For categorical variables, the number and percent of subjects in each response category will be presented.

### 14.3. Previous and Concomitant Medications

Previous and concomitant medications will be coded. Previous medications will be those that were discontinued before the surgery day. Concomitant medications will be those continued through, or started on, the surgery day and up through the 12-hour assessment period. In addition, those medications taken after the 12-hour assessment period through the follow-up interview for an AE will be considered concomitant medications. Medications taken after the 12-hour assessment through the follow-up call that were not taken for an AE will not be collected on the CRF or summarized. Previous medications and concomitant medications will be summarized by treatment in separate tables. Number and percentage of subjects receiving each coded medication will be presented by treatment. Additionally, concomitant medications taken by greater than or equal to 5% of subjects in at least one treatment group will be presented.

### 14.4. Efficacy Analysis

#### Primary Efficacy Endpoint

- Time to confirmed perceptible pain relief (TCPR)

#### Secondary Efficacy Endpoint

- Percentage of subjects with confirmed perceptible pain relief from 45 minutes to successively earlier minutes in one-minute increments (Test NPX versus PBO)

#### Tertiary Efficacy Endpoints

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

### 14.5. Statistical Hypotheses and Treatment Comparisons

The primary hypothesis for the primary endpoint is

$$H_0 : S_1(t) = S_2(t) \text{ (all } t)$$



$$H_A : S_1(t) \neq S_2(t) \text{ (at least some } t)$$

where  $S_1(t)$  and  $S_2(t)$  are the survival functions of each compared treatment, respectively.

To control the family-wise Type I error rate at 0.05 for primary and secondary endpoints, the fixed sequence testing with fallback method will be used [4]. Table 5 presents the order of the tests and the assigned  $\alpha$  values for each ordered test. Testing will commence with an assigned alpha = 0.049 and an alpha value of 0.001 will be reserved for the comparison of Test NPX and placebo on the percentage of subjects with confirmed perceptible relief from 45 minutes to successively earlier minutes in one-minute increments.

**Table 5: Order of Tests and Assigned Alpha Values**

	<b>Pre-Assigned <math>\alpha</math>-value</b>	<b><math>\alpha</math>-value available if previous test positive</b>	<b><math>\alpha</math>-value available if previous test(s) negative</b>
TCPR: Test NPX vs PLACEBO	0.049	Not Applicable	Not Applicable
TCPR: Test NPX vs [REDACTED]	None	0.049	None
TCPR: Test NPX vs [REDACTED]	None	0.049	None
Percentage of subjects with confirmed perceptible pain relief from 45 minutes to successively earlier minutes in one-minute increments: Test NPX vs Placebo	0.001	0.05	0.001

## 14.6. Data Computations and Data Imputations

### 14.6.1. Time to [REDACTED] Confirmed Perceptible [REDACTED] Pain Relief (TCPR)

[REDACTED] Time to confirmed perceptible pain relief is defined as the time (in minutes) to perceptible pain relief as indicated on the first stopwatch, provided that the subject also stopped the second stopwatch indicating meaningful pain relief. [REDACTED]

[REDACTED]  
[REDACTED] subjects who do not have relief by 12 hours, who take rescue medication before having relief, or who discontinue before having relief will have time to relief set to 12 hours and be censored at 12 hours

**14.6.2.** [REDACTED]

[REDACTED]

**14.7. Analysis Methods**

**14.7.1. [REDACTED] Time to Confirmed Perceptible Pain Relief**

[REDACTED] time to confirmed perceptible pain relief (TCPR), [REDACTED] will be analyzed using survival data analysis. The survival function (cumulative proportions of subjects with pain relief at each time point) and the median survival time will be estimated by the Kaplan-Meier method for each treatment. The survival functions will be compared using the Wilcoxon test.

Sensitivity analyses will be conducted for TCPR assessing the impact of censoring at the time of rescue medication for subjects not having meaningful relief, and also the impact of censoring at the time of perceptible relief for subjects not having meaningful relief. Further details regarding these analyses will be provided in the statistical analysis plan.

**14.7.2. Earliest Statistically Significant Separation of Test NPX and Placebo on Percentage of Subjects with Confirmed Perceptible Relief**

The earliest time of separation between Test NPX and placebo will be established by comparing the percentage of subjects with confirmed perceptible pain relief starting from 45 minutes to successively earlier minutes in one-minute increments, until statistical significance is no longer achieved. The dichotomized response will be analyzed using logistic regression analysis.

**14.7.3.**

[REDACTED]

[REDACTED]

**14.7.4.**

[REDACTED]

[REDACTED]

[Section 14.6.2.](#)

**14.7.5.**

[REDACTED]

[REDACTED]

**14.7.6.**

[REDACTED]

[REDACTED]

**14.7.7.**

[REDACTED]

[REDACTED]

[Section 14.6](#)

**14.7.8. Subgroup Analyses**

Time to confirmed perceptible relief will be analyzed based on the following subgroups: age group (<18 years, ≥18 years), gender, race (white, non-white) and baseline categorical pain

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

(moderate, severe). The survival function and the median survival time will be estimated by the Kaplan-Meier method within each subgroup.

## **14.8. Safety Analysis**

The safety analysis will be based on the safety analysis set.

### **14.8.1. Adverse Events**

Treatment-emergent AEs are those with a start date and time at or after the time of study drug administration. All summaries described below are for treatment-emergent AEs except where noted. Non- treatment-emergent AEs will be provided in a listing.

The number and percentage of subjects experiencing AEs will be tabulated by treatment, system organ class and preferred term using the MedDRA coding dictionary. The number and percentage of subjects experiencing treatment-related AEs will also be presented by system organ class and preferred term. Treatment-related AEs will include events marked as being at least possibly related to study treatment. The number and percentage of subjects with AEs will be presented by severity. Subjects will be counted only once for each system organ class and preferred term by selecting the most severe event. The number of subjects with the most commonly reported adverse events (those reported by 5% or more in any one treatment group) will be summarized by treatment, system organ class and preferred term. The number of subjects with adverse events will also be summarized by demographic characteristics: age group (<18 years, ≥18 years), gender, and race.

The number and percentage of subjects experiencing SAEs or who discontinued the study due to an AE will be presented by system organ class and preferred term. These displays will include all AEs, not just treatment-emergent AEs.

## **15. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS**

The investigator (s)/institutions(s) will permit study related monitoring, audits, IRB/IEC review, and regulatory inspection(s) by providing access to the source data/documents.

### **15.1. Study Monitoring**

Before an investigational site can enter a subject into the study, a representative of JJCI will visit the investigational study site to:

- Determine the adequacy of the facilities
- Discuss with the investigator(s) and other personnel their responsibilities the site's responsibility with regard to protocol adherence as well as the study and monitoring responsibilities of J&J or its representatives. These responsibilities will be documented in a Clinical Study Agreement between J&J and the investigator.

During the study, a monitor from J&J or representative will have regular contacts with the investigational site, for the following:

- Provide information and support to the investigator(s)
- Confirm that facilities remain acceptable
- Confirm that the investigational team is adhering to the protocol, that data are being accurately recorded in the CRFs, and that investigational product accountability checks are being performed
- Perform source data verification. This includes a comparison of the data in the CRFs with the subject's source documents, e.g., written medical records, electronic medical records at the hospital or practice, subject diaries/journals and other records relevant to the study. This will require direct access to all original records for each subject (e.g., clinic charts).
- Record and report all protocol deviations not previously sent to J&J. The Investigator should not deviate from the Protocol except if specified by the Sponsor or within the Protocol.
- Confirm AEs and SAEs have been properly documented on CRFs and confirm any SAEs have been forwarded to J&J and those SAEs that met criteria for reporting to Regulatory Authority/Competent Authority and/or IRB/IEC, as applicable, have been forwarded to the required authorities. The monitor will be available between visits if the investigator(s) or other staff needs information or study-related direction.

**COMPANY CONFIDENTIAL**

Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

## **15.2. Audits and Inspections**

Authorized representatives of J&J, a regulatory/competent authority, an IRB/IEC representative may visit the site to perform audits or inspections, including source data verification. The purpose of a J&J audit or inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, GCP guidelines of the ICH E6, and any applicable regulatory requirements. The investigator should notify the Sponsor (e.g., Study Manager, Monitor) listed within the protocol or other contacts provided immediately if contacted by a regulatory agency about an inspection.

**COMPANY CONFIDENTIAL**

## **16. QUALITY CONTROL AND QUALITY ASSURANCE**

The clinical study will be executed and reported following GCPs, all applicable regulatory requirements and applicable SOPs, including quality control of documents. Deviations will be analyzed and documented. To ensure compliance, the Sponsor may conduct one or several quality assurance audit(s). Please see [Section 15.2](#) for more details regarding the audit process.

## **17. DATA HANDLING AND RECORDKEEPING**

### **17.1. Case Report Forms / Electronic Data Capture**

All data will be collected on source documents first and then recorded in an Electronic Data Capture (EDC) system. The EDC system is the database where pertinent study data are collected such as demography, subject randomization, efficacy assessments, adverse events, and subject disposition. EDC CRFs should be completed for each included subject. The completed pages of the EDC system are the sole property of the Sponsor and should not be made available in any form to third parties, except for authorized representatives of the Sponsor or appropriate regulatory authorities, without written permission from the Sponsor.

It is the Investigator's responsibility to ensure completion and to review and approve all information captured in the EDC. The subject's data in the EDC system must be electronically signed by the Investigator. These signatures serve to attest that the information contained in the EDC system is true. At all times, the Investigator has final personal responsibility for the accuracy and authenticity of all clinical and laboratory data entered in the EDC. Subject source documents are the Investigator's/physician's subject records maintained at the study site. In cases where the source documents are the hospital or the physician's chart, the information collected in the EDC must match those charts. All final data recorded in EDC system will be copied into files and kept by the Sponsor. A copy of these files will also be kept at the clinical site. All data provided in the CRF must be supported by source document.

### **17.2. Source Documents**

The investigator/institution should maintain adequate and accurate source documents and trial records that include all pertinent observations on each of the site's trial subjects. Source data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (e.g., via an audit trail). Inspection and Retention of Records

### **17.3. Inspection and Retention of Records**

To enable evaluations and/or audits from regulatory authorities or the Sponsor, the investigator agrees to keep records including the identity of all participating subjects (sufficient information to link records, e.g., CRFs and hospital records), all original signed informed consent forms, copies of all CRFs, SAE forms, source documents, and detailed records of treatment disposition.

The PI must maintain all documentation relating to the study according to ICH guidelines or as specified in the Clinical Study Agreement for a period of 2 years after the last marketing application approval or per local requirements if longer than 2 years, or if not approved 2



Test Naproxen Sodium 220 mg Tablet

Protocol: CCSPAA000457

Version 1: 11 May 2018

Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

years following the discontinuance of the test article for investigation. If it becomes necessary for J&J or the Regulatory Authority to review any documentation relating to the study, the Investigator must permit access to such records.

If the investigator relocates, retires, or for any reason withdraws from the study, the Sponsor should be prospectively notified. The study records must be transferred to an acceptable designee, e.g., another investigator. The investigator must obtain Sponsor's written permission before disposing of any records, even if retention requirements have been met.

## **18. PUBLICATION POLICY**

Publication of study results by the Investigator is discussed in the Clinical Study Agreement, as appropriate. Results from this study may be published in the form of oral or written presentations at scientific meetings or as one or more peer-reviewed journal articles. In these cases, no information on individual subjects will be revealed.

## **19. LIST OF REFERENCES**

1. Averbuch M, Katzper M. Baseline pain and response to analgesic medications in the postsurgery dental pain model. *J Clin Pharmacol* 2000;40:133-137.
2. Cooper SA. Single-dose analgesic studies: the upside and downside of assay sensitivity. In: Max M, Portenoy R, Laska E, eds. *Advances in pain research and therapy*. Vol 18. New York, NY: Raven Press, Ltd., 1991:117-24.
3. Data on file for “PKPD Model-Based Meta-Analysis of the Comparative Onset of Relief from Acute Pain for Naproxen Sodium Bicarbonate”, McNeil Consumer Healthcare, Fort Washington, PA, 2017.
4. Wiens, BL. A fixed sequence Bonferroni procedure for testing multiple endpoints. *Pharmaceutical Statistics* 2003; 2:211-215.

Test Naproxen Sodium 220 mg Tablet  
Protocol: CCSPAA000457  
Version 1: 11 May 2018  
Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

## **20. APPENDICES**

**COMPANY CONFIDENTIAL**

Test Naproxen Sodium 220 mg Tablet  
Protocol: CCSPAA000457  
Version 1: 11 May 2018  
Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

**APPENDIX 1:**

**PAIN RATING SCALES/ CATEGORICAL PAIN INTENSITY SCALE**

Finish the statement “My pain at this time is” by checking the appropriate box.

No Pain (0)

Mild Pain (1) Moderate Pain (2) Severe Pain (3)

**0-10 PAIN INTENSITY - NUMERICAL RATING SCALE (PI-NRS)**

Circle the number that best represents your pain.

No pain 0 1 2 3 4 5 6 7 8 9 10 Very severe pain

[Redacted response area]

Test Naproxen Sodium 220 mg Tablet  
Protocol: CCSPAA000457  
Version 1: 11 May 2018  
Version 2: 19 July 2018 - Administrative Change/Non-substantial Amendment 1

**APPENDIX 2:** [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]